Biotech Co.*
(Country;
Symbol)

Pharma Co.
(Country)

Change from original
agreement

Terms/Details (Date)

ChemDiv Inc.*

Merck KGaA(Germany)

Renewed an expanded agreement for ChemDiv toserve as a provider ofdiscovery libraries of lead-like small molecules through2009

The companies signed the original dealthree years ago (2/14)

Critical
Therapeutics
Inc.*

Beckman CoulterInc.

Exercised option to continuelicensing patent rights forHigh Mobility Group Box 1technology to develop animmunoassay to detect anddiagnose inflammatorydiseases

Beckman Coulter paid an unspecifiedproduct development fee and has agreedto begin formal product development ofan HMGB1 diagnostic; Critical Therapeuticsis entitled to a milestone payment androyalties (2/13)

Entelos Inc.
(LSE:ENTL)

NV Organon(the Netherlands)

Extended a two-year rheumatoid arthritis collab-oration with NV Organon

The partners have collaborated since 2001to develop the Entelos Rheumatoid Arthritis PhysioLab platform; financial terms werenot disclosed (2/20)

Genfit
(France; Paris:
ALGFT)

Sanofi-Aventis(France)

Renewed agreement forthe pharmacological charac-terization of Sanofi's drugcandidates and the selectionof those that best act on aninnovative target involvedin metabolic and inflammatory mechanisms

The agreement was originally signed in 1999 (2/27)

Genfit
(France; Paris:
ALGFT)

Solvay(Belgium)

Renewed agreement tofocus on compounds selected that act on a completelynew target

Solvay is due to start a Phase I trial of thefirst product; the collaboration, first signedin 2002, was created to identify and develop new selective nuclear receptor modulators playing a key role in the metabolismof lipoproteins and the formation ofatherosclerosis (2/27)

Halozyme
Therapeutics
Inc. (AMEX:HTI)

BaxterHealthcareCorp.

Expanded alliance givingBaxter additional rights touse Hylenex with two ofits small-molecule drugs

Halozyme gets an up-front payment of $10M, a $20M equity investment at apremium, $10M in prepaid royalties, andup to $25M in regulatory and commercialmilestone payments (2/14)

Idera
Pharmaceuticals
Inc. (AMEX:IDP)

Novartis AG Switzerland)

Extended research agreement to develop Toll-likereceptor 9 agonists totreat asthma and allergy

The agreement, signed in June 2005, isextended for one year (3/6)

Ingenuity
Systems*

Merck & Co. Inc.

Extended and expandedagreement for Merck'saccess to the IngenuityPathways Analysis softwarefor biological interpretationand analysis

Financial terms were not disclosed (2/14)

Jerini AG
(Germany;
BE:JI4)

BaxterInternationalInc.

Extended existingagreement in hemophiliato include two new drugdevelopment programsinvolving two new targets

The initial pact was signed in 2001 andextended in 2004; Jerini is receiving anundisclosed up-front payment and researchfunding for each of the new programs andcould receive milestone and royalty payments as well (2/7)**

Vion
Pharmaceuticals
Inc. (VION)
(VNP4010M)

SAFC (member ofSigma-AldrichGroup)

Extended manufacturingagreement for Vion's leadcancer drug, Cloretazine until September2009

Financial terms were not disclosed (3/22)

XOMA Ltd.
(XOMA)

TakedaPharmaceuticalCo. Ltd.

Expanded agreementto discover and developmonoclonal antibodytherapeutics beyond indications of immunology to the field of oncology

The agreement followed the expirationof XOMA's agreement with Novartis AGfor oncology indications; expanding theTakeda deal into oncology ups the pre-royalty value to $230M in up-front, R&Dfunding, milestone and other payments(2/28)

Bavarian
Nordic A/S(Denmark;CSE:BAVA)

GlaxoSmithKlineplc (UK)

Terminated agreement forthe production and marketing of Imvamune, a third-generationsmallpox vaccine

The companies originally signed the dealin 2004 (2/2)

Maxygen
Inc. (MAXY)

F. Hoffmann-La Roche Ltd.(Switzerland)

Roche is ending deal for theco-development andcommercialization ofMaxygen's preclinical-stageMAXY-VII program

MAXY-VII is a next-generation Factor VIIprogram for acute bleeding indications;Roche's decision was based on the inabilityof the parties to establish an appropriateanimal model (12/13)

Optimer
Pharmaceuticals
Inc.*

ParPharmaceuticalCos. Inc.

Terminated collaborationfocused on Difimicin (PAR-101/OPT-80) to treat Clostridiumdifficile-associated diarrhea

Optimer regained North American rights,ending a collaboration that began in April2005; Par gets a one-time $20M paymentup front, and is eligible to receive a $5Mmilestone payment; it also would get single-digit royalties on product sales forseven years (2/27)

Replidyne Inc.
(RDYN)

ForestLaboratories Inc.

Terminated collaboration tocommercialize faropenemmedoxomil

Replidyne regains all U.S. adult and pediatric rights; the FDA issued a non-approvable letter for four adult indications lastOctober (2/7)

Scolr
Pharma Inc.
(AMEX:DDD)

WyethConsumerHealthcare

Wyeth is terminating itslicense to use Scolrtechnology in productscontaining ibuprofen

Scolr already received $2.1M in paymentsunder the December 2005 deal; it plans tocontinue development of a 12-hour extended-release ibuprofen product (3/15)

Trimeris Inc.(TRMS)

F. Hoffmann-La Roche Ltd.(Switzerland)

Roche is returning all rightsto next-generation HIVfusion inhibitors that fallunder their 2000 agreement

Roche also is returning rights to developproducts under a 1999 deal, except thatterms for Fuzeon remained unchanged;Roche would get nominal royalties on salesof TRI-1144 from the 2000 deal; it also cancontinue research on HIV gp41 fusioninhibitor peptides, while Trimeris has anoption to co-develop those products (3/15)